Hyperion Defi, Inc.
HYPDHyperion Defi, Inc. in brief
Hyperion Defi, Inc. is a listed company in the Biotechnology industry, based in the USA. Its market value was $52 M on 9 October 2026, which makes it the 21,121st largest listed company in the world and the 3,840th largest in the USA on this site. In the year to December 2025 it had sales of $2 M and a net loss of $20 M. Its largest business segments by sales in 2025 were Digital Assets (98%) and Ophthalmic Technology (2%). Its shares trade under the symbol HYPD (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Hyperion Defi, Inc.
We were organized as a corporation under the laws of the State of Florida on March 12, 2014 under the name “PGP Holdings V, Inc.” On May 5, 2014, we changed our name to Eyenovia, Inc. On October 6, 2014, we reincorporated in the State of Delaware by merging into Eyenovia, Inc., a Delaware corporation. On July 1, 2025, we changed our name to Hyperion DeFi, Inc. Our principal executive office is located at 23461 S. Pointe Drive, Suite 390, Laguna Hills, CA 92653, and our telephone number is (833) 393-6684. We maintain a website at www.hyperiondefi.com, to which we regularly post copies of our press releases as well as additional information about us. The information contained on, or that can be accessed through, our website is not a part of this report. We have included our website address in this report solely as an inactive textual reference.
Hyperion Defi, Inc. timeline
- 2016
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2018
- 🔔· approximateInitial public offering on Nasdaq
- 🔔Initial public offering as Eyenovia, Inc.Final prospectus filed with the SEC on 25 January 2018; shares registered for exchange trading on 24 January 2018.
- 2021
- 💰Record revenue of $14 millionFY2021, the highest of the 5 years on record.
- 2025
- ✎Renamed Hyperion Defi, Inc.Formerly Eyenovia, Inc..
Events of Hyperion Defi, Inc. from SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,857 (Jan 2020) · #3,432 (Jan 2021) · #4,391 (Jan 2022) · #4,683 (Dec 2022) · #4,401 (Jul 2023) · #3,836 (Jan 2024) · #3,820 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 26.1×
- Price / book
- 1.3×
- Free cash flow yield
- -58.0%
- Net margin
- -985.0%
- Operating margin
- -2336.0%
- Return on equity
- -48.0%
- Liabilities / assets
- 20.7%
- Revenue growth
- +1250.0%
- R&D / revenue
- 235.8%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1M | +1250.0% | $-47M | $-45M | -5593.8% |
| Dec 2024 | $0M | — | $-49M | $-50M | -83033.3% |
| Dec 2023 | $0M | — | $-25M | $-27M | — |
| Dec 2022 | — | — | $-27M | $-28M | — |
| Dec 2021 | $14M | +600.0% | $-13M | $-13M | -91.3% |
| Dec 2020 | $2M | — | $-20M | $-20M | -988.5% |
| Dec 2019 | — | — | $-21M | $-21M | — |
| Dec 2018 | — | — | $-17M | $-17M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-15M | — | — | $-9.40 | — |
| Dec 2024 | $-30M | $0M | $-30M | $-59.81 | — |
| Dec 2023 | $-24M | $3M | $-27M | $-53.15 | — |
| Dec 2022 | $-25M | $1M | $-26M | $-0.83 | — |
| Dec 2021 | $-21M | $1M | $-22M | $-0.49 | — |
| Dec 2020 | $-6M | $0M | $-7M | $-0.94 | — |
| Dec 2019 | $-19M | $0M | $-19M | $-1.47 | — |
| Dec 2018 | $-13M | $0M | $-13M | $-1.82 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $1M (+170.0% on a year earlier), net income $40M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Oct 2, 20268-KCurrent reportAgreement ended · Results of operations · Regulation FD disclosure · Other events
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 12, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Jul 8, 20268-KCurrent reportDirectors or officers changed
- Jul 1, 20268-KCurrent reportShareholder vote
- Jun 5, 20268-KCurrent reportOther events
- May 15, 202610-QQuarterly report · period to Mar 2026
- May 14, 20268-KCurrent reportResults of operations · Regulation FD disclosure · Other events
- May 6, 20268-KCurrent reportOther events
- May 5, 2026DEF 14AProxy statement
- Mar 30, 202610-KAnnual report · period to Dec 2025
Official filings of Hyperion Defi, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $2 M
- Operating income
- $-47 M
- Net income
- $-20 M
For year ending December-2025
Balance sheet
- Total assets
- $52 M
- Total liabilities
- $11 M
- Total equity
- $41 M
As of December-2025
Top 35 institutional investors in Hyperion Defi, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 575,568 | +108,770 (+23.30%) | 3.70% | $2 M | Nov 13, 2026 |
| 2 | Franklin Templeton Inc | 392,639 | -3,300 (-0.83%) | 2.53% | $1 M | Nov 12, 2026 |
| 3 | Morgan Stanley | 300,046 | +62,060 (+26.08%) | 1.93% | $1 M | Nov 13, 2026 |
| 4 | Arrington Capital Management, LLC | 280,777 | -17,000 (-5.71%) | 1.81% | $1 M | Nov 16, 2026 |
| 5 | Geode Capital Management, LLC | 166,570 | +35,863 (+27.44%) | 1.07% | $1 M | Nov 6, 2026 |
| 6 | Almanack Investment Partners, LLC. | 161,323 | -7,690 (-4.55%) | 1.04% | $1 M | Nov 3, 2026 |
| 7 | Jane Street Group, LLC | 148,363 | +20,872 (+16.37%) | 0.95% | $1 M | Nov 12, 2026 |
| 8 | Oppenheimer & Co Inc | 127,703 | +1,338 (+1.06%) | 0.82% | $0 M | Oct 26, 2026 |
| 9 | BlackRock, Inc. | 122,865 | +8,465 (+7.40%) | 0.79% | $0 M | Nov 13, 2026 |
| 10 | Marshall Wace, LLP | 114,285 | New | 0.74% | $0 M | Nov 13, 2026 |
| 11 | UBS Group AG | 101,438 | +68,259 (+205.73%) | 0.65% | $0 M | Nov 10, 2026 |
| 12 | Citadel Advisors LLC | 77,106 | +20,807 (+36.96%) | 0.50% | $0 M | Nov 16, 2026 |
| 13 | Vanguard Fiduciary Trust Co | 74,455 | 0 (0.00%) | 0.48% | $0 M | Nov 13, 2026 |
| 14 | State Street Corp | 54,357 | 0 (0.00%) | 0.35% | $0 M | Nov 12, 2026 |
| 15 | Intesa Sanpaolo S.p.A. | 53,000 | New | 0.34% | $0 M | Nov 16, 2026 |
| 16 | Invesco Ltd. | 47,988 | New | 0.31% | $0 M | Nov 12, 2026 |
| 17 | Accurate Wealth Management, LLC | 35,430 | New | 0.23% | $0 M | Oct 20, 2026 |
| 18 | Northern Trust Corp | 32,086 | +1,190 (+3.85%) | 0.21% | $0 M | Nov 16, 2026 |
| 19 | Price T Rowe Associates Inc /MD/ | 20,500 | 0 (0.00%) | 0.13% | $0 M | Nov 16, 2026 |
| 20 | Peak6 LLC | 20,000 | 0 (0.00%) | 0.13% | $0 M | Nov 13, 2026 |
| 21 | R Squared Ltd | 19,355 | New | 0.12% | $0 M | Nov 6, 2026 |
| 22 | XTX Topco Ltd | 12,782 | +493 (+4.01%) | 0.08% | $0 M | Nov 16, 2026 |
| 23 | Jpmorgan Chase & Co | 12,308 | -3,799 (-23.59%) | 0.08% | $0 M | Nov 12, 2026 |
| 24 | Concurrent Investment Advisors, LLC | 11,307 | New | 0.07% | $0 M | Oct 16, 2026 |
| 25 | Nations Financial Group Inc, /ia/ /adv | 11,125 | 0 (0.00%) | 0.07% | $0 M | Nov 5, 2026 |
Show all 35: investors 26 to 35
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Sanctuary Advisors, LLC | 10,800 | 0 (0.00%) | 0.07% | $0 M | Nov 13, 2026 |
| 27 | Vanguard Global Advisers, LLC | 8,695 | +8,596 (+8682.83%) | 0.06% | $0 M | Nov 13, 2026 |
| 28 | Tower Research Capital LLC (TRC) | 4,656 | +3,804 (+446.48%) | 0.03% | $0 M | Nov 16, 2026 |
| 29 | SBI Securities Co., Ltd. | 1,584 | +365 (+29.94%) | 0.01% | $0 M | Oct 22, 2026 |
| 30 | Wells Fargo & Company/mn | 1,233 | +3 (+0.24%) | 0.01% | $0 M | Nov 16, 2026 |
| 31 | Royal Bank Of Canada | 419 | New | 0.00% | $0 M | Nov 16, 2026 |
| 32 | Caitong International Asset Management Co., Ltd | 67 | +63 (+1575.00%) | 0.00% | $0 M | Oct 29, 2026 |
| 33 | BNP Paribas Financial Markets | 54 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 34 | Barclays PLC | 3 | -1,804 (-99.83%) | 0.00% | $0 M | Nov 6, 2026 |
| 35 | Group One Trading LLC | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
Mutual funds holding Hyperion Defi, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Putnam Small Cap Value FundPutnam Investment Management, LLC | 286,628 | $1 M | 1.8% | 0.34% | new | May 31, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 290,757 | $1 M | 1.9% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 176,041 | $1 M | 1.1% | <0.01% | +109% | Jun 30, 2026 |
| 🇺🇸 Putnam VT Small Cap Value FundPutnam Investment Management, LLC | 109,172 | $0 M | 0.70% | 0.28% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 37,727 | $0 M | 0.24% | <0.01% | +23% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 33,999 | $0 M | 0.22% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc. | 20,500 | $0 M | 0.13% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 13,409 | $0 M | 0.09% | <0.01% | +45% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 10,255 | $0 M | 0.07% | <0.01% | +29% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 3,922 | $0 M | 0.03% | <0.01% | +354% | May 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 2,293 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 212 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 12 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Hyperion Defi, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | David R. KnoxChief Financial Officer | Shares withheld for tax | -19,563 | — | — | 287,556 | Form 4 |
| filed | Hyunsu JungSee Remarks, Director | Shares withheld for tax | -40,000 | — | — | 1.35 M | Form 4 |
| filed | Rachel JacobsonDirector | Grant or award | +58,917 | — | — | 115,218 | Form 4 |
| filed | Ellen R. StrahlmanDirector | Grant or award | +58,917 | — | — | 150,078 | Form 4 |
| filed | Michael S. GeltzeilerDirector | Grant or award | +58,917 | — | — | 146,932 | Form 4 |
| filed | Happy David WaltersDirector | Grant or award | +58,917 | — | — | 170,847 | Form 4 |
| filed | Hyunsu JungSee Remarks, Director | Buy | +500 | $3.640 | $2 K | 1.39 M | Form 4 |
| filed | Hyunsu JungSee Remarks, Director | Buy | +500 | $3.680 | $2 K | 1.39 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Hyperion Defi, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-80 reverse split
Trading halts
- 2025-07-03 13:31 UTC, code LUDP, resumed 13:36 UTC
- 2025-06-30 13:34 UTC, code LUDP, resumed 13:39 UTC
- 2025-06-17 19:00 UTC, code LUDP, resumed 19:05 UTC
- 2025-03-20 10:55 UTC, code T3, resumed 11:30 UTC
- 2025-02-01 00:50 UTC, code T3, resumed 14:00 UTC
Fails to deliver
- : 78 shares at $3.37
- : 1,320 shares at $3.82
- : 12,913 shares at $3.73
- : 8,491 shares at $3.62
- : 2,697 shares at $3.41
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Hyperion Defi, Inc. scorecard#
Passes 2 of the 12 checks that could be worked out: strongest in valuation (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 9, 2026.
Valuation1 of 3
- –P/E below its peers' medianNo P/E on file.
- ✓Price to book below its peers' median1.3×Price to book 1.3× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median26.1×Price to sales 26.1× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-58.0%Free cash flow is -58.0% of the market value.
- –Earnings yield above the 10-year Treasury yieldNo P/E on file.
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-9.40 vs -59.81Diluted EPS -9.40 in fiscal 2025 against -59.81 the year before (report's currency).
- ✗Net income higher than five years earlier-$45 M-$45 M in fiscal 2025 against -$20 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$45 MNet income -$45 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-324.1%-324.1% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 4
- ✓Short-term assets cover short-term liabilities2.7×Current ratio 2.69 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-123.0×Operating income -123.0 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-6.44Z-score -6.44 (distress zone) for fiscal 2025.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Hyperion Defi, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0.8+1319%100% | 0.1+1414%100% | 0.0—100% | — | 14+600%100% | 2.0—100% | — | — | — | — | |
| Cost of revenue | 0.3−92.3%37.3% | 3.9+24438%6849% | 0.0r0.0—423% | — | 1.6+100%11.4% | 0.8—40.0% | — | — | — | — | |
| Gross profit | 0.5—62.7% | −3.9—−6749% | −0.0—−323% | — | 12+933%88.6% | 1.2—60.0% | — | — | — | — | |
| Research and development | 1.9−86.8%235% | 14+11.5%25225% | 13−3.0%342641% | 13−9.9%— | 15r15+11.1%106% | 13r13−5.2%668% | 14+26.8%— | 11+191%— | 3.8+28.7%— | 3.0—— | |
| Selling, general and administrative | 17+19.8%2111% | 14+15.4%24998% | 12—327922% | — | — | — | — | — | — | — | |
| General and administrative | — | — | 12−8.1%328244% | 14+28.0%— | 11r11+38.6%75.5% | 7.6r7.7+5.8%381% | 7.2+17.4%— | 6.1+366%— | 1.3+131%— | 0.6—— | |
| Operating expenses | 47+5.3%5806% | 45+76.7%78255% | 25r25−5.6%670563% | 27+5.9%— | 25r25+21.1%182% | 21−1.5%1049% | 21+23.5%— | 17+236%— | 5.1+45.2%— | 3.5—— | |
| Operating income | −47—−5744% | −49—−85005% | −25—−670886% | −27—— | −13r−13—−93.0% | −20—−989% | −21—— | −17—— | −5.1—— | −3.5—— | |
| Interest and finance income | 0.2−5.5%29.5% | 0.3−63.4%443% | 0.7—18316% | — | — | — | — | — | 0.0+59.0%— | 0.0—— | |
| Interest expense and finance costs | 1.6−37.3%192% | 2.5+4.7%4333% | 2.4+71.9%62631% | 1.4+256%— | 0.4+2175%2.8% | 0.0—0.9% | 0—— | — | — | — | |
| Other non-operating income (expense) | 1.4—173% | −1.1—−1884% | −1.9—−48974% | −1.1r0.2−770%— | 0.2r0.0—1.2% | — | — | — | — | — | |
| Income tax | −0.0—−3.8% | — | — | — | — | — | 0—— | 0—— | 0—— | 0—— | |
| Net income attributable to shareholders | −45—−5571% | −50—−86889% | −27—−719860% | −28—— | −13—−91.3% | −20—−988% | −21—— | −17—— | −5.1—— | −3.5—— | |
| Earnings per share, basic | -9.40—— | -59.81—— | -53.15r-0.66—— | -0.83—— | -0.49—— | -0.94—— | -1.47—— | -1.82—— | -2.19—— | -1.56—— | |
| Earnings per share, diluted | -9.40—— | -59.81—— | -53.15r-0.66—— | -0.83—— | -0.49—— | -0.94—— | -1.47—— | -1.82—— | -2.19—— | -1.56—— | |
| Shares, weighted average (basic) | 5.0+500%— | 0.8+62.4%— | 0.5r41−98.5%— | 34+27.8%— | 26+25.0%— | 21—— | — | — | — | — | |
| Shares, weighted average (diluted) | 5.0+500%— | 0.8+62.4%— | 0.5r41−98.5%— | 34+27.8%— | 26+25.0%— | 21+46.7%— | 14+51.4%— | 9.5+304%— | 2.3+3.4%— | 2.3—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 6.3r6.4+197%12.2% | 2.1−85.7%57.8% | 15−35.1%51.6% | 23+17.5%73.7% | 19−31.4%61.5% | 28+100%83.7% | 14−28.3%96.3% | 20+276%98.6% | 5.2+55.0%93.0% | 3.4—98.7% | |
| Inventory | — | — | 0.1—0.4% | — | — | — | — | — | — | — | |
| Other current assets | 0.3r0.2+232%0.6% | 0.1r0.6−92.9%2.7% | 1.4+14.7%4.7% | 1.2+62.0%3.8% | 0.7r0.7+62.1%2.3% | 0.5+131%1.3% | 0.2+48.2%1.3% | 0.1+257%0.7% | 0.0+1491%0.7% | 0.0—0.1% | |
| Current assets | 7.2+162%14.0% | 2.8−86.6%75.4% | 21−25.1%71.9% | 28+25.6%89.1% | 22r22−34.1%69.5% | 33+133%98.5% | 14−27.8%97.6% | 20+276%99.2% | 5.3+56.0%93.7% | 3.4—98.7% | |
| Property, plant and equipment | — | — | 3.4+161%11.7% | 1.3+1.9%4.2% | 1.3+221%4.0% | 0.4+71.9%1.2% | 0.2+528%1.6% | 0.0+31.4%0.2% | 0.0−35.3%0.5% | 0.0—1.3% | |
| Right-of-use (leased) assets | 0.4−42.1%0.8% | 0.7−56.9%19.6% | 1.7+29.0%5.8% | 1.3—4.2% | — | — | — | — | — | — | |
| Other intangible assets | — | — | 2.1—7.4% | — | — | — | — | — | — | — | |
| Total assets | 52+1311%100% | 3.7−87.3%100% | 29−7.3%100% | 31−2.0%100% | 32−6.6%100% | 34+131%100% | 15−26.6%100% | 20+255%100% | 5.6+64.4%100% | 3.4—100% | |
| Accounts payable | 0.3−83.7%0.6% | 2.0r2.2+11.5%53.3% | 1.8+22.7%6.1% | 1.4−11.5%4.6% | 1.6+10.4%5.1% | 1.5−5.2%4.3% | 1.5+2.1%10.5% | 1.5+513%7.5% | 0.2−18.4%4.4% | 0.3—8.8% | |
| Current liabilities | 2.7−83.2%5.2% | 16+68.4%437% | 9.5+111%33.1% | 4.5−59.6%14.5% | 11−38.6%35.3% | 18+525%53.7% | 2.9−6.0%19.8% | 3.1+461%15.5% | 0.6+30.4%9.8% | 0.4—12.3% | |
| Lease liabilities (non-current) | 0.2−71.2%0.4% | 0.7−44.5%19.6% | 1.3r1,134+42.4%4.5% | 0.9—2.9% | — | — | — | — | — | — | |
| Total liabilities | 11−36.1%20.7% | 17−15.3%457% | 20+43.3%68.7% | 14+23.3%44.5% | 11−39.8%35.4% | 19+529%54.9% | 3.0−5.8%20.1% | 3.1+468%15.7% | 0.6—9.8% | — | |
| Retained earnings | −241—−465% | −195—−5325% | −145—−506% | −118—−381% | −90—−285% | −77—−228% | −58—−392% | −37—−182% | −19—−341% | −14—−412% | |
| Shareholders' equity | 41—79.3% | −13−246%−357% | 9.0−47.8%31.3% | 17−15.8%55.5% | 20+33.7%64.6% | 15+30.4%45.1% | 12−30.4%79.9% | 17+231%84.3% | 5.1+69.2%90.2% | 3.0—87.7% | |
| Total liabilities and equity | 52+1311%100% | 3.7−87.3%100% | 29−7.3%100% | 31−2.0%100% | 32−6.6%100% | 34+131%100% | 15−26.6%100% | 20+255%100% | 5.6+64.4%100% | 3.4—100% | |
| Shares outstanding | 8.7+476%— | 1.5+165%— | 0.6r46−98.4%— | 37+29.0%— | 28+13.8%— | 25+46.1%— | 17+49.1%— | 11+347%— | 2.6+13.2%— | 2.3—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | 1.1+44.1%1968% | 0.8+155%20681% | 0.3+38.8%— | 0.2+132%1.6% | 0.1+522%4.8% | 0.0−19.8%— | 0.0−24.9%— | 0.0+98.9%— | 0.0—— | |
| Share-based compensation | 6.4+274%783% | 1.7−31.8%2972% | 2.5−33.7%65960% | 3.8+30.5%— | 2.9+16.2%20.6% | 2.5−1.1%124% | 2.5+55.5%— | 1.6+292%— | 0.4+15228%— | 0.0—— | |
| Cash from operating activities | −15—−1816% | −30—−52534% | −24—−629431% | −25—— | −21—−149% | −6.4—−319% | −19—— | −13—— | −4.7—— | −3.2—— | |
| Capital expenditure | — | −0.2—−282% | −2.8—−75194% | −0.5—— | −1.2—−8.8% | −0.3—−13.1% | −0.2—— | −0.0—— | −0.0—— | −0.0—— | |
| Intangible assets bought | — | — | −1.1—−29653% | — | — | — | — | — | — | — | |
| Cash from investing activities | −72—−8845% | −0.2—−282% | −4.0—−104847% | −0.9—— | −1.6—−11.6% | −0.3—−13.1% | −0.2—— | −0.0—— | −0.0—— | −0.0—— | |
| Debt repaid | — | — | — | — | −0.1—−0.5% | 0—0.0% | — | — | — | — | |
| Shares issued | — | — | — | — | — | 13—637% | 0r13—— | 0r25—— | 0—— | — | |
| Cash from financing activities | 91+419%11193% | 18−11.3%30618% | 20−8.0%522646% | 22+0.2%— | 21+2.8%153% | 21+54.4%1043% | 14−51.1%— | 28+318%— | 6.6+59.5%— | 4.1—— | |
| Change in cash | 4.3—531% | −13—−22198% | −8.0—−211631% | −4.5—— | −1.0−107%−7.4% | 14—711% | −5.6−139%— | 14+677%— | 1.9+108%— | 0.9—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 1.9+453%100% | 0.8+168%100% | 0.4—100% | 0.2+1559%100% | 0.5*+1666%100% | 0.3+18516%100% | 0*−100%— | 0.0+195%100% | 0.0*+985%100% | 0.0—100% | 0.0—100% | 0.0—100% | 0.0*—100% | |
| Cost of revenue | — | — | — | — | 0.3*−90.2%61.1% | 0*−100%0.0% | 0*−100%— | 0.0−100.0%0.3% | 3.1*+119688%11039% | 0.1—8155% | 0.5—2167% | 0.2r0.0—4066% | 0.0*—100% | |
| Gross profit | 1.6—84.1% | 0.8+168%100% | 0.4—100% | 0.2+1565%100% | 0.2*—38.9% | 0.3—100% | 0*—— | 0.0—99.7% | −3.1*—−10939% | −0.1—−8055% | −0.5—−2067% | −0.2—−3966% | 0*—0.0% | |
| Research and development | 0.5−85.4%28.1% | 0.0−99.4%0.3% | 0.1−91.3%16.4% | 0.3−57.4%117% | 0.2*−90.4%38.1% | 0.4−89.2%124% | 0.7−85.3%— | 0.7−84.8%4572% | 2.0*−51.7%6984% | 3.5—213658% | 4.6—20319% | 4.4—88756% | 4.1*—156999% | |
| Selling, general and administrative | 17+5.6%877% | 3.8+46.2%468% | 3.9−49.0%1096% | 4.5+89.4%1840% | 4.5*+41.2%913% | 2.6−30.4%858% | 7.7+104%— | 2.4—16116% | 3.2*−5.7%11419% | 3.7—229483% | 3.8—16614% | — | 3.4*—131396% | |
| General and administrative | — | — | — | — | — | — | — | 2.4−34.8%16116% | — | — | 3.8—16614% | 3.6r3.8—72846% | 3.4*—131396% | |
| Operating expenses | −38−263%−2015% | −39—−4848% | −31−467%−8569% | −8.5−379%−3475% | 40*+144%8052% | −4.1−157%−1364% | 8.4−25.6%— | 3.0−69.8%20689% | 16*+119%58299% | 7.2—443140% | 11—49594% | 10r10—201658% | 7.5r7.5*—288395% | |
| Operating income | 40—2100% | 40+806%4948% | 31—8669% | 8.7—3575% | −40*—−8013% | 4.4—1464% | −8.4—— | −3.0—−20589% | −19*—−69238% | −7.3—−451196% | −12—−51661% | −10—−205624% | −7.5*—−288395% | |
| Interest and finance income | 0.7+430%34.5% | 0.1+56.9%8.5% | 0.2+843%57.8% | 0.2+591%100.0% | 0.1*+498%28.0% | 0.0−2.5%14.5% | 0.0−66.2%— | 0.0−70.8%240% | 0.0*−88.3%82.7% | 0.0—2769% | 0.1—287% | 0.1—2422% | 0.2*—7674% | |
| Interest expense and finance costs | 0.9−50.9%47.9% | 0.2+3.1%28.4% | 0.2−55.8%65.4% | 0.2−61.2%92.5% | 0.2*−57.6%45.3% | 0.2−63.0%73.7% | 0.5−21.6%— | 0.6−14.3%3950% | 0.5*−22.2%1885% | 0.6—37053% | 0.7—2979% | 0.7—13592% | 0.7*—26289% | |
| Other non-operating income (expense) | −0.5−151%−24.2% | −0.5−123%−63.2% | −0.1—−15.9% | 0.1—44.4% | −0.0*—−0.1% | 2.2—726% | −0.3−153%— | −0.5—−3076% | −0.5*—−1793% | −0.6—−34211% | 0.6—2805% | −0.7—−13124% | −0.5*—−19335% | |
| Net income attributable to shareholders | 40—2075% | 40+497%4885% | 31—8653% | 8.8—3619% | −40*—−8014% | 6.6—2190% | −8.7—— | −3.5—−23665% | −20*—−71031% | −7.9—−485406% | −11—−48856% | −11—−218748% | −8.0*—−307730% | |
| Earnings per share, basic | — | 1.24+377%— | 1.01—— | 0.30—— | — | 0.26—— | -2.50—— | -1.59—— | — | -9.07r-0.11—— | -16.65r-0.21—— | -18.75r-0.23—— | — | |
| Earnings per share, diluted | — | 1.23+2360%— | 0.92—— | 0.26—— | — | 0.05—— | -2.50—— | -1.59—— | — | -9.07r-0.11—— | -16.65r-0.21—— | -18.75r-0.23—— | — | |
| Shares, weighted average (basic) | 16+160%— | 16+160%— | 14+303%— | 11+385%— | — | 6.0+593%— | 3.5+430%— | 2.2+276%— | — | 0.9r70—— | 0.7r53—— | 0.6r47—— | — | |
| Shares, weighted average (diluted) | 16−45.6%— | 16−45.6%— | 17+384%— | 13+480%— | — | 29+3230%— | 3.5+430%— | 2.2+276%— | — | 0.9r70—— | 0.7r53—— | 0.6r47—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 6.6—4.5% | 6.6−19.4%4.5% | 9.6+27.9%8.5% | 7.4+87.6%10.5% | 6.3r6.4+197%12.2% | 8.2+14.4%9.9% | 7.5+227%13.5% | 3.9−50.7%65.8% | 2.1−85.7%57.8% | 7.2—31.5% | 2.3—12.1% | 8.0—30.5% | 15—51.6% | |
| Inventory | — | — | — | — | — | — | — | — | — | 3.0—13.0% | 3.1—16.1% | 3.5—13.4% | 0.1—0.4% | |
| Other current assets | 0.3—0.2% | 0.3−64.2%0.2% | 0.2+176%0.2% | 0.1−89.9%0.2% | 0.3r0.2+232%0.6% | 0.9−12.7%1.0% | 0.1−94.3%0.1% | 1.2−41.6%19.8% | 0.1r0.6−92.9%2.7% | 1.0—4.3% | 1.4—7.3% | 2.0—7.7% | 1.4—4.7% | |
| Current assets | 16—10.7% | 16+71.5%10.7% | 13+37.5%11.4% | 8.8+70.7%12.6% | 7.2+162%14.0% | 9.1−22.3%11.0% | 9.4+28.9%16.9% | 5.2−64.3%86.2% | 2.8−86.6%75.4% | 12—51.3% | 7.3—38.3% | 14—55.2% | 21—71.9% | |
| Property, plant and equipment | — | — | — | — | — | — | 0.0−99.2%0.0% | — | — | 2.8—12.1% | 3.0—16.0% | 3.2—12.1% | 3.4—11.7% | |
| Right-of-use (leased) assets | 0.3—0.2% | 0.3−33.3%0.2% | 0.2−63.5%0.2% | 0.3−47.0%0.5% | 0.4−42.1%0.8% | 0.5−61.5%0.6% | 0.6−59.7%1.0% | 0.6−58.2%10.7% | 0.7−56.9%19.6% | 1.3—5.6% | 1.4—7.4% | 1.5—5.9% | 1.7—5.8% | |
| Other intangible assets | — | — | — | — | — | — | — | — | — | 6.1—26.9% | 6.1—32.2% | 6.1—23.4% | 2.1—7.4% | |
| Total assets | 146—100% | 146+76.7%100% | 113+103%100% | 70+1071%100% | 52+1311%100% | 83+263%100% | 56+193%100% | 6.0−77.1%100% | 3.7−87.3%100% | 23—100% | 19—100% | 26—100% | 29—100% | |
| Accounts payable | 0.2—0.1% | 0.2−84.3%0.1% | 0.1−84.6%0.1% | 0.4−64.3%0.6% | 0.3−83.7%0.6% | 1.1−27.6%1.4% | 0.9−37.2%1.6% | 1.2−44.1%20.1% | 2.0r2.2+11.5%53.3% | 1.6—6.9% | 1.4—7.6% | 2.1—8.2% | 1.8—6.1% | |
| Current liabilities | 4.1—2.8% | 4.1+2.8%2.8% | 5.5−46.6%4.9% | 4.5−70.4%6.4% | 2.7−83.2%5.2% | 4.0−74.4%4.9% | 10−34.9%18.5% | 15−8.3%252% | 16+68.4%437% | 16—69.2% | 16—83.4% | 16—62.9% | 9.5—33.1% | |
| Lease liabilities (non-current) | 0.0—0.0% | 0.0−85.4%0.0% | 0.1−88.2%0.0% | 0.1−77.8%0.2% | 0.2−71.2%0.4% | 0.3−59.1%0.4% | 0.5−51.9%0.9% | 0.6−47.6%10.0% | 0.7−44.5%19.6% | 0.8—3.7% | 1.0—5.2% | 1.1—4.4% | 1.3r1,134—4.5% | |
| Total liabilities | 4.2—2.9% | 4.2−65.1%2.9% | 11−38.8%9.9% | 12−26.3%16.5% | 11−36.1%20.7% | 12−36.9%14.5% | 18−14.3%32.9% | 16−35.6%262% | 17−15.3%457% | 19—83.7% | 21—112% | 24—93.1% | 20—68.7% | |
| Retained earnings | −161—−110% | −161—−110% | −201—−178% | −232—−331% | −241—−465% | −201—−243% | −207—−373% | −199—−3322% | −195—−5325% | −175—−769% | −167—−882% | −156—−598% | −145—−506% | |
| Shareholders' equity | 142—97.1% | 142+101%97.1% | 102+173%90.1% | 58—83.5% | 41—79.3% | 71r71+1802%85.5% | 37r37—67.1% | −9.7−634%−162% | −13−246%−357% | 3.7—16.3% | −2.4—−12.5% | 1.8—6.9% | 9.0—31.3% | |
| Total liabilities and equity | 146—100% | 146+76.7%100% | 113+103%100% | 70+1071%100% | 52+1311%100% | 83+263%100% | 56+193%100% | 6.0−77.1%100% | 3.7−87.3%100% | 23—100% | 19—100% | 26—100% | 29—100% | |
| Shares outstanding | 15—— | 15+116%— | 15+215%— | 11+304%— | 8.7+476%— | 7.2−91.7%— | 4.9−91.3%— | 2.8−94.0%— | 1.5+165%— | 86—— | 56—— | 47—— | 0.6r46—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | 0.3*+7.3%1060% | 0.3*—17691% | 0.3*—1306% | 0.2—4962% | 0.3*—10719% | |
| Share-based compensation | 6.8+41.6%354% | 1.6—192% | 1.6−71.2%456% | 1.8+545%739% | 1.8*+977%356% | −1.3−397%−445% | 5.7+949%— | 0.3−48.8%1900% | 0.2*−71.3%584% | 0.5—27877% | 0.5—2391% | 0.5—10940% | 0.6*—22102% | |
| Cash from operating activities | −13—−672% | −1.7*—−206% | −2.9*—−810% | −4.2—−1718% | −4.1*—−818% | −2.8*—−933% | −3.4*—— | −4.4—−30182% | −6.1*—−21752% | −5.9*—−365776% | −8.2*—−36130% | −9.9—−198112% | −6.3*—−244195% | |
| Capital expenditure | — | — | — | — | — | — | — | — | −0.0*—−0.0% | −0.0*—−99.9% | −0.0*—−202% | −0.1—−2285% | −0.1*—−5610% | |
| Intangible assets bought | — | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | |
| Cash from investing activities | −4.8—−249% | 8.5*—1051% | −5.5*—−1532% | −1.5—−603% | −6.3*—−1273% | −20*—−6648% | — | — | −0.0*—−0.0% | −0.0*—−99.9% | −0.0*—−202% | −0.1—−2285% | −0.1*—−5610% | |
| Cash from financing activities | 16−80.7%844% | −9.9*−142%−1217% | 11*−79.5%3010% | 6.6+5.6%2705% | 8.6*+723%1732% | 24*+118%7810% | 53*+1966%— | 6.3+99.7%42502% | 1.0*+70.0%3717% | 11*—666631% | 2.5*—11249% | 3.1—62746% | 0.6*—23726% | |
| Change in cash | −1.5−242%−76.8% | −3.0*−536%−372% | 2.4*−33.6%668% | 0.9−48.3%384% | −1.8*—−359% | 0.7*−85.9%228% | 3.6*—— | 1.8—12320% | −5.1*—−18035% | 4.9*—300756% | −5.7*—−25084% | −6.9—−137652% | −5.9*—−226078% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Hyperion Defi, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Digital Assets$1 M98%—
- Ophthalmic Technology$0 M1.8%-83%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Hyperion Defi, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Chief executive | $9.3 M | $4.6 M | $2.0 M | $89 |
| 2024Chief executive | $808 K | $510 K | $413 K | $4 |
| 2023Chief executive | $775 K | $1.2 M | $626 K | $52 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Hyperion Defi, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 2 · Auditor changed 1 · Directors and officers 8 · Material agreement 6 · Agreement ended 1 · New debt 2 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 3 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Agreement endedResults announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changedResults announced | 8-K | |
| Directors and officersUnregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officersMaterial agreement | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Delisting noticeDirectors and officers | 8-K | |
| Shareholder rights changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officersBylaws or fiscal year changed | 8-K | |
| Directors and officersMaterial agreementNew debtUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2025 | $50 M | Private placement after listing | $50 to $250 million | 5 | equity, options | SEC |
| Mar 2020 | $6 M | Private placement after listing | $2 to $10 million | 82 | equity, options | SEC |
| Jul 2017 | $6 M | No. 2 | $2 to $10 million | 10 | equity, options | SEC |
| Jul 2016 | $4 M | No. 1 | $2 to $10 million | 4 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 50% of workforce | Restructuring planSEC 8-K | “The Company is implementing a reduction in force affecting approximately 50% of its workforce.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Hyperion Defi, Inc. compares in Biotechnology
- Market cap$52 M · higher than 27% of 726
- Revenue$2 M · higher than 30% of 647
- Net margin-985.0% · higher than 0% of 408
- Revenue growth1250.0% · higher than 98% of 438
- Price / sales26.1× · lower than 26% of 339
- Price / book1.3× · lower than 73% of 534
- FCF yield-58.0% · higher than 21% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Hyperion Defi, Inc.🇺🇸 | $52 M | — | -985.0% | +1250.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 9, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, value.today research, SEC filing.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Hyperion Defi, Inc.? Verify and update this profile — free
Show Hyperion Defi, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.